Clinical Research Directory
Browse clinical research sites, groups, and studies.
Extension Study of NS-089/NCNP-02 in DMD
Sponsor: Nippon Shinyaku Co., Ltd.
Summary
This is the extension study of NS-089/NCNP-02 (Study NCNP/DMT02), which is designed to assess the safety, tolerability and efficacy of NS-089/NCNP-02 in patients with Duchenne muscular dystrophy (DMD).
Official title: A Phase II, Open-Label, Extension Study of NS-089/NCNP-02 in Patients With Duchenne Muscular Dystrophy
Key Details
Gender
MALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2021-06-23
Completion Date
2027-04-30
Last Updated
2025-07-20
Healthy Volunteers
No
Conditions
Interventions
NS-089/NCNP-02
The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
NS-089/NCNP-02
The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
Locations (2)
Kagoshima University Hospital
Kagoshima, Japan
National Center of Neurology and Psychiatry
Tokyo, Japan